Fidelis Capital Partners LLC Has $1.54 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Fidelis Capital Partners LLC boosted its position in shares of Danaher Co. (NYSE:DHR) by 12.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,164 shares of the conglomerate’s stock after purchasing an additional 795 shares during the period. Fidelis Capital Partners LLC’s holdings in Danaher were worth $1,535,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Kovack Advisors Inc. lifted its holdings in shares of Danaher by 3.4% during the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after buying an additional 41 shares during the last quarter. Gilbert & Cook Inc. raised its position in Danaher by 2.5% during the fourth quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after acquiring an additional 42 shares in the last quarter. Grimes & Company Inc. raised its position in Danaher by 0.6% during the fourth quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock valued at $1,696,000 after acquiring an additional 43 shares in the last quarter. Harbour Investments Inc. lifted its stake in Danaher by 3.0% in the third quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock valued at $426,000 after acquiring an additional 45 shares during the last quarter. Finally, Dakota Community Bank & Trust NA grew its position in Danaher by 16.4% in the fourth quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock worth $73,000 after acquiring an additional 45 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 11.10% of the company’s stock.

Danaher Stock Up 1.0 %

NYSE DHR opened at $207.73 on Monday. Danaher Co. has a twelve month low of $196.80 and a twelve month high of $281.70. The stock has a market cap of $148.47 billion, a PE ratio of 39.34, a PEG ratio of 2.66 and a beta of 0.83. The firm has a 50-day simple moving average of $224.58 and a 200 day simple moving average of $244.76. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the company posted $2.09 earnings per share. On average, research analysts forecast that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.32 per share. The ex-dividend date is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a yield of 0.62%. This is an increase from Danaher’s previous quarterly dividend of $0.27. Danaher’s payout ratio is currently 24.24%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on DHR shares. Royal Bank of Canada restated an “outperform” rating and set a $277.00 price target (down previously from $299.00) on shares of Danaher in a report on Thursday, January 30th. Citigroup cut their target price on Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Barclays decreased their price target on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research note on Friday, December 13th. Finally, The Goldman Sachs Group set a $250.00 target price on Danaher in a research report on Wednesday, January 15th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.